Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials von Rosenstock, Julio, Marquard, Jan, Laffel, Lori M, Neubacher, Dietmar, Kaspers, Stefan, Cherney, David Z, Zinman, Bernard, Skyler, Jay S, George, Jyothis, Soleymanlou, Nima, Perkins, Bruce A

Volltext

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial von PERKINS, Bruce A, CHERNEY, David Z. I, JOHANSEN, Odd-Erik, PARTRIDGE, Helen, SOLEYMANLOU, Nima, TSCHIRHART, Holly, ZINMAN, Bernard, FAGAN, Nora M, KASPERS, Stefan, WOERLE, Hans-Juergen, BROEDL, Uli C

Volltext

Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1 von Nevo, Ori, Soleymanlou, Nima, Wu, Yuan, Xu, Jing, Kingdom, John, Many, Ariel, Zamudio, Stacy, Caniggia, Isabella

Volltext

Molecular Evidence of Placental Hypoxia in Preeclampsia von Soleymanlou, Nima, Jurisica, Igor, Nevo, Ori, Ietta, Francesca, Zhang, Xin, Zamudio, Stacy, Post, Martin, Caniggia, Isabella

Volltext

TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design von Trachtman, Howard, Kretzler, Matthias, Desmond, Hailey E., Choi, Wansuk, Manuel, Raymond C., Soleymanlou, Nima

Volltext

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes von Perkins, Bruce A, Cherney, David Z I, Soleymanlou, Nima, Lee, Justin A, Partridge, Helen, Tschirhart, Holly, Zinman, Bernard, Mazze, Roger, Fagan, Nora, Kaspers, Stefan, Woerle, Hans-Juergen, Broedl, Uli C, Johansen, Odd Erik

Volltext

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes von Johnston, Curtis K, Eudy-Byrne, Rena J, Elmokadem, Ahmed, Nock, Valerie, Marquard, Jan, Soleymanlou, Nima, Riggs, Matthew M, Liesenfeld, Karl-Heinz

Volltext

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus von Cherney, David Z.I, Perkins, Bruce A, Soleymanlou, Nima, Maione, Maria, Lai, Vesta, Lee, Alana, Fagan, Nora M, Woerle, Hans J, Johansen, Odd Erik, Broedl, Uli C, von Eynatten, Maximilian

Volltext

Patient preferences for newer oral therapies in type 2 diabetes von Savarese, Gianluigi, Sharma, Abhinav, Pang, Christianne, Wood, Richard, Soleymanlou, Nima

Volltext

Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition von Lytvyn, Yuliya, Kimura, Karen, Peter, Nuala, Lai, Vesta, Tse, Josephine, Cham, Leslie, Perkins, Bruce A., Soleymanlou, Nima, Cherney, David Z.I.

Volltext

Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review von Farsani, Soulmaz Fazeli, Brodovicz, Kimberly, Soleymanlou, Nima, Marquard, Jan, Wissinger, Erika, Maiese, Brett A

Volltext

Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition von Lytvyn, Yuliya, Kimura, Karen, Peter, Nuala, Lai, Vesta, Tse, Josephine, Cham, Leslie, Perkins, Bruce A., Soleymanlou, Nima, Cherney, David Z.I.

Volltext

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus von Cherney, David Zi, Perkins, Bruce A, Soleymanlou, Nima, Har, Ronnie, Fagan, Nora, Johansen, Odd Erik, Woerle, Hans-Juergen, von Eynatten, Maximilian, Broedl, Uli C

Volltext

Kidney Effects of Empagliflozin in People with Type 1 Diabetes von Cherney, David Z I, Bjornstad, Petter, Perkins, Bruce A, Rosenstock, Julio, Neubacher, Dietmar, Marquard, Jan, Soleymanlou, Nima

Volltext

2216-PUB: Patient Preferences for Newer Oral Therapies in Type 2 Diabetes von SAVARESE, GIANLUIGI, SHARMA, ABHINAV, PANG, CHRISTIANNE, WOOD, RICHARD, GEORGE, JYOTHIS T., SOLEYMANLOU, NIMA

Volltext

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration von Škrtić, Marko, Yang, Gary K., Perkins, Bruce A., Soleymanlou, Nima, Lytvyn, Yuliya, von Eynatten, Maximilian, Woerle, Hans J., Johansen, Odd Erik, Broedl, Uli C., Hach, Thomas, Silverman, Melvin, Cherney, David Z. I.

Volltext

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function von van Bommel, Erik J M, Lytvyn, Yuliya, Perkins, Bruce A, Soleymanlou, Nima, Fagan, Nora M, Koitka-Weber, Audrey, Joles, Jaap A, Cherney, David Z I, van Raalte, Daniël H

Volltext

20-OR: The Renal and Vascular Effects of Combined SGLT2 and Angiotensin Converting Enzyme Inhibition von LYTVYN, YULIYA, KIMURA, KAREN, PETER, NUALA, LAI, VESTA S., TSE, JOSEPHINE, CHAM, LESLIE, PERKINS, BRUCE A., SOLEYMANLOU, NIMA, CHERNEY, DAVID

Volltext

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial von Shimada, Akira, Hanafusa, Toshiaki, Yasui, Atsutaka, Lee, Ganghyuck, Taneda, Yusuke, Sarashina, Akiko, Shiki, Kosuke, George, Jyothis, Soleymanlou, Nima, Marquard, Jan

Volltext

Kidney Effects of Empagliflozin in People with Type 1 Diabetes: PO1008 von Cherney, David, Bjornstad, Petter, Perkins, Bruce A., Rosenstock, Julio, Neubacher, Dietmar, George, Jyothis T., Marquard, Jan, Soleymanlou, Nima

Volltext